Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00

Key Points

• Needham raised its price target to $80 (from $58), maintaining a "buy" rating and implying roughly a 31% upside versus the current share price.
• Positive Phase 3 X‑TOLE2 topline results for azetukalner in focal‑onset seizures drove a sharp stock rally and volume surge, with the company and analysts pointing to an intended NDA submission target in Q3 2026.
• However, Xenon recently missed quarterly EPS estimates and the CEO sold a large portion of his holdings, while analysts caution that the post‑readout rally may price in aggressive uptake and that safety, competitive and commercial risks remain.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) had its price objective lifted by Needham & Company LLC from $58.00 to $80.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Needham & Company LLC's price objective would suggest a potential upside of 31.32% from the stock's current price.

Several other brokerages have also recently issued reports on XENE. Stifel Nicolaus set a $66.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Bank of America restated a "buy" rating on shares of Xenon Pharmaceuticals in a research report on Monday. Chardan Capital raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, November 19th. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a research note on Friday, January 9th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $57.92.

Xenon Pharmaceuticals Price Performance

XENE traded up $18.98 on Monday, reaching $60.92. 9,234,438 shares of the company's stock were exchanged, compared to its average volume of 1,143,636. The stock has a market cap of $5.07 billion, a PE ratio of -13.97 and a beta of 0.91. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $62.91. The stock's fifty day moving average price is $42.25 and its 200-day moving average price is $41.24.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same period last year, the business posted ($0.84) earnings per share. As a group, research analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the firm's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares in the company, valued at $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.07% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Large investors have recently made changes to their positions in the company. Cinctive Capital Management LP boosted its position in Xenon Pharmaceuticals by 1.1% in the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company's stock valued at $1,045,000 after buying an additional 263 shares in the last quarter. Arizona State Retirement System lifted its holdings in Xenon Pharmaceuticals by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company's stock worth $774,000 after purchasing an additional 334 shares in the last quarter. State of Wyoming grew its holdings in Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 350 shares in the last quarter. Quarry LP lifted its holdings in shares of Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 500 shares in the last quarter. Finally, Altfest L J & Co. Inc. boosted its position in shares of Xenon Pharmaceuticals by 6.5% in the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company's stock valued at $369,000 after acquiring an additional 501 shares during the period. Institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Company release — Xenon announced positive topline results from the Phase 3 X‑TOLE2 study of azetukalner in focal‑onset seizures, reporting the trial met its primary endpoint and supporting the drug’s efficacy. GlobeNewswire: Topline Data
• Positive Sentiment: Major press coverage & market reaction — Multiple outlets reported the strong Phase 3 readout and noted a sharp stock rally and volume surge as investors reacted to the efficacy data. Blockonomi: Stock Rockets
• Positive Sentiment: Regulatory path indicated — Company commentary and analyst notes point to an intended NDA submission target in Q3 2026 and plans to pursue epilepsy plus additional neuropsychiatric indications, creating a near‑term catalyst runway. Seeking Alpha: NDA timing & pipeline
• Neutral Sentiment: Trading mechanics — Nasdaq briefly halted XENE trading for “news pending” ahead of the announcement, a typical market response to major clinical readouts that can amplify short‑term volatility. (Market bulletin noted halt at 06:55 AM ET.)
• Negative Sentiment: Valuation and risk concerns — Independent analysts flag that the post‑readout rally may price in aggressive uptake; they also warn of a crowded anti‑seizure market, notable adverse‑event rates called out in commentary, and commercial execution risks that could temper longer‑term returns. Seeking Alpha: Valuation & risks

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.